Company profile
ImmuCell Corporation
NASDAQ: ICCC · Healthcare · Biotechnology
#514 of 1,418 Healthcare companies by revenue48th-percentile growth
EA Score
64CFH 79DQ 40GM 61SS 72
v0.1 · 65/100 weight · provisional
↑ listing tenure, Piotroski F · ↓ filing timeliness, disclosure history
Methodology →Revenue TTM
$29.9M
Rev growth YoY (TTM)
+9.6%
Net income (FY)
-$1.0M
Employees
73
as of 2026-08-18
Market cap
$88.2M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$27.6M$27.6M2025
Net income-$1.0M-$1.0M2025
Operating income$1.6M$1.6M2025
Total assets$42.5M$42.5M2025
Liabilities$15.5M$15.5M2025
Equity$27.1M$27.1M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY23
FY23
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ImmuCell Corporation’s revenue?
ImmuCell Corporation booked $27.6M in FY2025 revenue, growing 4.3% year over year — about the middle of the pack among Healthcare companies we track, at a -3.8% net margin.
Peers · Healthcare
Bionano Genomics, Inc.48DLowell Farms Inc.——American Shared Hospital Services59CSensus Healthcare, Inc.51DCue Biopharma, Inc.50DINNOCAN PHARMA Corp59CNeighbors
Cumberland →Key facts
CEOF. Olivier Te Boekhorst
SectorHealthcare
IndustryBiotechnology
HeadquartersPortland, ME
ExchangeNASDAQ: ICCC
Employees73
IPO date1987-05-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.